Viroksavir is under clinical development by Traws Pharma and currently in Phase I for Haemophilus influenzae Type B Infections. According to GlobalData, Phase I drugs for Haemophilus influenzae Type B Infections have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Viroksavir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Viroksavir overview

Viroksavir is under development for the treatment of pandemic influenza, seasonal influenza, haemophilus influenzae type A infections, haemophilus influenzae type B infections. It acts by targeting cap-independent endonuclease.

Traws Pharma overview

Onconova Therapeutics (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib and ON123300. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting the medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partnered with biopharmaceutical companies and medical organizations in the US. Onconova is headquartered in Newtown, Pennsylvania, the US.

For a complete picture of Viroksavir’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.